Veru Inc. (VERU)

Market Cap	85.24M
Revenue (ttm)	16.89M
Net Income (ttm)	-36.35M
Shares Out	146.58M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,778,440
Open	0.6501
Previous Close	0.6553
Day's Range	0.5815 - 0.6501
52-Week Range	0.4500 - 1.4200
Beta	-0.79
Analysts	Strong Buy
Price Target	4.00 (+587.88%)
Earnings Date	Aug 7, 2025

About VERU

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 1990
• Employees: 210
• Stock Exchange: NASDAQ
• Ticker Symbol: VERU
• Website: https://verupharma.com

Financial Performance

In 2024, Veru Inc.'s revenue was $16.89 million, an increase of 3.62% compared to the previous year's $16.30 million. Losses were -$37.80 million, -59.42% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 587.88% from the latest price.

Price Target

$4.0

(587.88% upside)

Analyst Consensus: Strong Buy